Sign in
ADCT Stock Price, Chart, Stats & News
ADC Therapeutics S.A.
Save
ADC Therapeutics S.A. (ADCT) does not currently pay a dividend.
161.53M
Market cap
–
Current P/E
–
Forward P/E
ADCT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 90.57% |
Operating margin | -133.21% |
Pretax margin | -175.50% |
Net margin | -175.31% |
Effective tax rate | -0.61% |
ROA | -44.14% |
ROE | 66.23% |
D/E | -2.36x |
Interest coverage ratio | -2.10x |
ADCT valuation
P/E | – |
P/S | 5.78x |
P/B | -2.99x |
P/CF | -3.94x |
P/FCF | -3.32x |
P/OCF | -3.94x |
PEG | -0.23x |
EV multiple | -2.75x |
About
ADC Therapeutics S. A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL).
Similar securities
Based on sector and market capitalization
Report issue